Learn what retatrutide is, how this next‑generation triple agonist (GLP‑1, GIP, and glucagon) works for weight loss, obesity, and metabolic health, and see key phase 2 clinical trial results on body‑weight reduction and cardiometabolic benefits.
Learn what marituglutide is, how its dual GLP-1/GIP “twincretin” mechanism works, and how it may outperform semaglutide for weight loss, glycemic control, and metabolic health in obesity and type 2 diabetes.
Learn what semaglutide is, how this GLP‑1 receptor agonist works in the pancreas, stomach, and brain, and why it’s transforming obesity, weight loss, and type 2 diabetes treatment with bariatric surgery–level results.
Discover how tirzepatide, a first‑in‑class dual GIP/GLP‑1 “twincretin,” delivers up to ~20% body weight reduction, improves cardiometabolic risk factors, and bridges the gap between obesity pharmacotherapy and metabolic surgery.
Discover how tirzepatide, a next‑generation dual GLP‑1/GIP agonist, delivers bariatric‑level weight loss, improves glycemic control, and sets a new standard for protein–peptide obesity drugs and metabolic disease management.
Discover how tirzepatide, a dual GIP and GLP‑1 receptor agonist, is redefining metabolic medicine with powerful HbA1c reductions and unprecedented weight loss results in obesity and type 2 diabetes clinical trials.
Learn what retatrutide is, how its triple agonist action on GLP‑1, GIP, and glucagon receptors works, and why early clinical trials show up to 24% weight loss and major improvements in blood sugar control.
Discover how oral small molecule GLP‑1 receptor agonists could replace weekly injections like semaglutide and tirzepatide, offering scalable, room‑temperature‑stable pills that transform obesity and type 2 diabetes care worldwide.
Discover how next‑generation mitochondrial uncouplers boost resting energy expenditure, burn liver and visceral fat, and improve insulin sensitivity by turning excess calories into heat instead of stored fat. Learn why this emerging obesity and NAFLD treatment could complement today’s appetite‑suppressing drugs.
Discover how oral GLP‑1 small molecule drugs could transform obesity and type 2 diabetes treatment. Learn how they work, why they may be cheaper and easier than injectables, and their potential to become “statins” for metabolic disease.
- 1
- 2